NC-PERCONA
20.12.2021 15:02:10 CET | Business Wire | Press release
Percona , a leader in open source database software and services, celebrated record growth for Q3 2021, including 44 percent Annual Recurring Revenue (ARR) growth year over year. With more than 10 million downloads of its open source projects and tools, Percona actively enables developers and database administrators in their roles powering business applications.
Percona brings together database distributions alongside open source tools and contributions to build enterprise-ready database products. This model represents the potential of the open source approach to make a real difference in how developers build the applications that their companies need and how DBAs manage their database environment most effectively.
“We support global retail customers with their critical payment infrastructure, and we plan ahead so that we can always deliver what our customers need. Percona offers round-the-clock expert support to ensure our databases are running at peak performance. We can rely on Percona’s unbiased approach as we consider any future deployments too,” said Delia Pedersoli, Chief Operating Officer at MultiPay.
Percona continues to take an independent approach to open source and databases, collaborating with a wide range of organizations across industries. Since inception, the company’s services and support expertise for managing, scaling, and optimizing database performance has been infrastructure agnostic. This supports customers to achieve value faster, deliver better availability for their applications and achieve flexibility in deployment to help their organizations win. Percona has recently expanded its approach, including the recent announcement of its new unified Percona Platform for multiple database distributions, management tools, private Database as a Service (DBaaS), and support.
“Our future as a company is based on packaging up our skills and experience in new ways, beginning with Percona Platform. The platform will make it easier for developers and DBAs to get the value of the work that we have put in over the years, bringing everything together in one place. We’ll continue to support customers running individual databases, whether they are running our distributions or not, as this is part of the value that open source provides to the market, as well as expanding how we deliver our expertise over time,” said Ann Schlemmer, President at Percona.
"Over the last decade-plus, the typical enterprise has seen a dramatic expansion in the number and type of databases leveraged. In many cases, the only thing that the databases have had in common was the fact that they were open source," said Stephen O'Grady, Principal Analyst with RedMonk. "This presented challenges for buyers, however, as negotiating with an ever-growing number of infrastructure vendors was both difficult to scale and limited the leverage buyers could bring to bear. What many have been looking for is a single vendor to supply them with support for multiple databases, and this is the exact opportunity Percona has targeted."
Percona was founded to support companies that wanted to run open source databases for their applications and remains fully committed to the ideals of free and open source software. The company celebrated its 15th anniversary in 2021, and has grown by embracing remote work and flexibility from the start. Today, Percona has staff based across 42 countries.
An overview of Percona’s anniversary is available at https://www.percona.com/about-percona/15th-anniversary and Percona Platform is available as a preview at https://www.percona.com/platform-preview .
Links
- Percona Products - https://www.percona.com/software
- Percona database optimization services - https://www.percona.com/solutions/optimize-database-performance
About Percona
Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.
Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, and Rent the Runway, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. For more information, visit www.percona.com .
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
